Itci stock zacks
ITCI earnings call for the period ending March 31, 2019. Intra-Cellular Therapies, Inc. (ITCI) Q1 2019 Earnings Call Transcript | The Motley Fool Latest Stock Picks Intra-Cellular up 10% ahead of presentation of ... Dec 10, 2019 · Intra-Cellular Therapies (ITCI +10%) perks up on modestly higher volume ahead of a presentation of lumateperone data tomorrow at the American College of Neuropsychopharmacology Annual Meeting in Holly ITCI Stock News - Fidelity Apr 02, 2020 · Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, today announced the grant to four new employees of inducement stock options to purchase an aggregate of 6,688 shares of its common stock and restricted stock units for an GRUB GrubHub — Stock Price and Discussion | Stocktwits Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures.
ITCI Intra-Cellular Therapies, Inc. Stock Quote
ITCI:NASDAQ GS Stock Quote - Intra-Cellular Therapies Inc ... Stock analysis for Intra-Cellular Therapies Inc (ITCI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ITCI - Intra-Cellular Ther Stock Price - Barchart.com Intra-Cellular Ther (ITCI) Intra-Cellular Ther (ITCI) (ITCI): Strong Industry, Solid Earnings Estimate Revisions Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 9:11AM CDT. Zacks Equity Research - ZACKS - Fri Mar 27, 9:11AM CDT A measure of how much a stock or commodity has risen or fallen over a one-year period ITCI - Intra-Cellular Ther News - Barchart.com Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 7:50AM CST Zacks Equity Research - ZACKS - Tue Jan 21, 7:50AM CST Investors need to pay close attention to Intra-Cellular (ITCI) stock based on the movements in … Is The Options Market Predicting A Spike In Intra-Cellular ...
Jan 21, 2020 · Investors in Intra-Cellular Therapies, Inc. ITCI need to pay close attention to the stock based on moves in the options market lately. That is because …
ITCI: Intra-Cellular Therapies Inc. Detailed Estimate. Get the latest Detailed Estimate from Zacks Investment Research. Mar 27, 2020 One stock that might be an intriguing choice for investors right now is Intra- Cellular Therapies, Inc. (ITCI - Free Report) . This is because this Feb 18, 2020 Intra-Cellular Therapies (ITCI) is likely to provide update on its commercialization plan for Caplyta, Zacks Equity Research February 18, 2020. Nov 19, 2019 Options Traders Expect Huge Moves in Intra-Cellular Therapies (ITCI) Stock. Zacks Equity Research November 19, 2019. ITCI. Trades from $1.
Intra-Cellular Therapies Inc (NASDAQ:ITCI) Receives $33.14 ...
ITCI earnings call for the period ending March 31, 2019. Intra-Cellular Therapies, Inc. (ITCI) Q1 2019 Earnings Call Transcript | The Motley Fool Latest Stock Picks Intra-Cellular up 10% ahead of presentation of ...
Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures.
ITCI Stock News - Fidelity Apr 02, 2020 · Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, today announced the grant to four new employees of inducement stock options to purchase an aggregate of 6,688 shares of its common stock and restricted stock units for an GRUB GrubHub — Stock Price and Discussion | Stocktwits Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures. Intra-Cellular: 4Q Earnings Snapshot Mar 02, 2020 · On a per-share basis, the New York-based company said it had a loss of 74 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks … Intra-Cellular Therapies Inc (NASDAQ:ITCI) Receives $33.14 ...
ITCI (Intra-Cellular Therapies) Stock Price and Chart ... Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock? Zacks: Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the ITCI Earnings Date, Forecast and Report (Intra-Cellular ... View Intra-Cellular Therapies' (NASDAQ:ITCI) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat. stock lists and powerful research tools with 30 days of MarketBeat All Access for just $1.00. Sign Up Now . Fundamental company data provided by Morningstar and Zacks Investment Implied Volatility Surging for Intra-Cellular (ITCI) Stock ... Jan 21, 2020 · Investors in Intra-Cellular Therapies, Inc. ITCI need to pay close attention to the stock based on moves in the options market lately. That is because the Feb 21, 2020 $36.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility?